Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17286608rdf:typepubmed:Citationlld:pubmed
pubmed-article:17286608lifeskim:mentionsumls-concept:C0026764lld:lifeskim
pubmed-article:17286608lifeskim:mentionsumls-concept:C1522690lld:lifeskim
pubmed-article:17286608lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:17286608lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:17286608pubmed:issue4lld:pubmed
pubmed-article:17286608pubmed:dateCreated2007-3-23lld:pubmed
pubmed-article:17286608pubmed:abstractTextNearly all patients with multiple myeloma (MM) relapse or become refractory to front-line therapy. Several salvage therapies have been explored, but the optimal combination regimen has not been defined. We performed a case-matched study comparing patients with relapsed/refractory MM receiving thalidomide-dexamethasone alone or the combination thalidomide-dexamethasone-liposomal pegylated doxorubicin.lld:pubmed
pubmed-article:17286608pubmed:languageenglld:pubmed
pubmed-article:17286608pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17286608pubmed:citationSubsetIMlld:pubmed
pubmed-article:17286608pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17286608pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17286608pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17286608pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17286608pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17286608pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17286608pubmed:statusMEDLINElld:pubmed
pubmed-article:17286608pubmed:monthAprlld:pubmed
pubmed-article:17286608pubmed:issn0902-4441lld:pubmed
pubmed-article:17286608pubmed:authorpubmed-author:LeoniPietroPlld:pubmed
pubmed-article:17286608pubmed:authorpubmed-author:OffidaniMassi...lld:pubmed
pubmed-article:17286608pubmed:authorpubmed-author:CorvattaLaura...lld:pubmed
pubmed-article:17286608pubmed:authorpubmed-author:BoccadoroMari...lld:pubmed
pubmed-article:17286608pubmed:authorpubmed-author:PalumboAntoni...lld:pubmed
pubmed-article:17286608pubmed:authorpubmed-author:BringhenSaraSlld:pubmed
pubmed-article:17286608pubmed:authorpubmed-author:FalcoPatrizia...lld:pubmed
pubmed-article:17286608pubmed:authorpubmed-author:MarconiMonica...lld:pubmed
pubmed-article:17286608pubmed:authorpubmed-author:PiersantelliM...lld:pubmed
pubmed-article:17286608pubmed:authorpubmed-author:AvontoIlariaIlld:pubmed
pubmed-article:17286608pubmed:authorpubmed-author:PolloniClaudi...lld:pubmed
pubmed-article:17286608pubmed:issnTypePrintlld:pubmed
pubmed-article:17286608pubmed:volume78lld:pubmed
pubmed-article:17286608pubmed:ownerNLMlld:pubmed
pubmed-article:17286608pubmed:authorsCompleteYlld:pubmed
pubmed-article:17286608pubmed:pagination297-302lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:meshHeadingpubmed-meshheading:17286608...lld:pubmed
pubmed-article:17286608pubmed:year2007lld:pubmed
pubmed-article:17286608pubmed:articleTitleThalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.lld:pubmed
pubmed-article:17286608pubmed:affiliationClinica di Ematologia Polo Ospedaliero-Universitario, Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, Italy. m.offidani@ao-umbertoprimo.marche.itlld:pubmed
pubmed-article:17286608pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17286608pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17286608lld:pubmed